TAS-116
- Generic Name
- TAS-116
- Drug Type
- Small Molecule
- Chemical Formula
- C25H26N8O
- CAS Number
- 1260533-36-5
- Unique Ingredient Identifier
- PLO044MUDZ
- Background
TAS-116 is under investigation in clinical trial NCT02965885 (A Study of TAS-116 in Patients With Solid Tumors).
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
Phase 1
Recruiting
- Conditions
- Retinoblastoma DeficiencyBladder CancerTreatment-Refractory Solid TumorsSCLCAdvanced Breast CancerSoft Tissue SarcomaEndometrial Cancer
- Interventions
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Brown University
- Target Recruit Count
- 27
- Registration Number
- NCT05655598
- Locations
- 🇺🇸
Lifespan Cancer Institute, Providence, Rhode Island, United States
AB122 Platform Study
Phase 1
Recruiting
- Conditions
- Advanced or Metastatic Solid TumorPancreatic Ductal AdenocarcinomaColorectal CancerNon-small Cell Lung CancerGastric CancerAlveolar Soft Part SarcomaEsophageal CancerHead and Neck CancerBiliary Tract Cancer
- Interventions
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 715
- Registration Number
- NCT04999761
- Locations
- 🇯🇵
A site selected by Taiho Pharmaceutical Co., Ltd., Wakayama, Japan
A Study of TAS-116 in Patients With Solid Tumors
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT02965885
- Locations
- 🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇮🇹Regina Elena National Cancer Institute, Roma, Italy
🇬🇧The Christie NHS Foundation Trust Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath